{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000205","form_type":"8-K","ticker":"TEVA","cik":"0000818686","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","filed_at":"2023-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.171697+00:00","generated_at":"2026-06-19T22:11:32.622166+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Teva reports FY2022 GAAP loss $2.12, non-GAAP EPS $2.52; Q4 rev $3.9B; guides 2023 lower","bullets":["Full-year 2022 revenues $14.9B (-6% YoY); GAAP diluted loss per share $2.12; non-GAAP diluted EPS $2.52.","Q4 2022 revenues $3.9B; GAAP diluted loss per share $1.10; non-GAAP diluted EPS $0.71.","2023 guidance: revenues $14.8-15.4B, non-GAAP diluted EPS $2.25-2.55, free cash flow $1.7-2.1B.","Goodwill impairment charges of $2.045B and legal settlements of $2.082B recorded in 2022.","CEO Richard Francis noted AUSTEDO US sales +20% YoY, generics in Europe +9% local currency."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000205","json":"https://secwatch.observer/filing/0001157523-23-000205.json","markdown":"https://secwatch.observer/filing/0001157523-23-000205.md","text":"https://secwatch.observer/filing/0001157523-23-000205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818686/000115752323000205/0001157523-23-000205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818686/000115752323000205/a53305953.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T22:11:32.622166+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"034aefede9bfa4c0ce0daad85b7fb2d68eebb9fc","claim":"TEVA PHARMACEUTICAL INDUSTRIES LTD updated its the year and the quarter ended December 31, 2022 guidance (initiated).","evidence_excerpt":"On February 8, 2023, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818686/000115752323000205/0001157523-23-000205-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year and the quarter ended December 31, 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}